Should you buy ADAPY stock?
Last updated:
Based on market data through , StockInvest.us rates Adaptimmune Therapeutics Plc (ADAPY) as a Sell Candidate with a technical score of -2.35 on its -10 to +10 scale. The rating is unchanged from the previous daily evaluation.
- Sell signal since
- Price since signal Down 11.95%
- 3-month trend forecast Up 50.17%
- High gross margin of 83.9%
- Strong return on equity of 143.8%
- Highly efficient cash conversion (100% FCF/OCF ratio)
Big movements in Adaptimmune Therapeutics Plc stock price on Monday moving 17.65% between high and low
(Market data through Aug 10, 2026)
The Adaptimmune Therapeutics Plc stock price fell by -6.67% on the last day (Monday, 10th Aug 2026) from $0.0300 to $0.0280. During the last trading day the stock fluctuated 17.65% from a day low at $0.0255 to a day high of $0.0300. The price has fallen in 7 of the last 10 days and is down by -24.32% for this period. Volume fell on the last day along with the stock, which is actually a good sign as volume should follow the stock. On the last day, the trading volume fell by -95 thousand shares and in total, 0 shares were bought and sold for approximately $0 .
The stock lies in the middle of a very wide and strong rising trend in the short term and a further rise within the trend is signaled. Given the current short-term trend, the stock is expected to rise 50.17% during the next 3 months and, with a 90% probability hold a price between $0.0307 and $0.0814 at the end of this 3-month period.
ADAPY Signals & Forecast
Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Some negative signals were issued as well, and these may have some influence on the near short-term development. The Adaptimmune Therapeutics Plc stock holds sell signals from both short and long-term Moving Averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $0.0289 and $0.0336. A break-up above any of these levels will issue buy signals. A sell signal was issued from a pivot top point on Friday, August 07, 2026, and so far it has fallen -6.67%. Further fall is indicated until a new bottom pivot has been found. Volume fell along with the price during the last trading day which is technical positive. One should, however, note that this stock may have low liquidity in periods, which increases the general risk. The very low volume increases the risk and reduces the other technical signals issued.
Support, Risk & Stop-loss for Adaptimmune Therapeutics Plc stock
Adaptimmune Therapeutics Plc finds support from accumulated volume at $0.0276 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.
In general the stock tends to have very controlled movements and therefore the general risk is considered very low. However, be aware of low or falling volume and make sure to keep an eye on the stock During the last day, the stock moved $0.0045 between high and low, or 17.65%. For the last week the stock has had daily average volatility of 21.05%
Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.
Trading Expectations (ADAPY) For The Upcoming Trading Day Of Tuesday 11th
For the upcoming trading day on Tuesday, 11th we expect Adaptimmune Therapeutics Plc to open at $0.0278, and during the day (based on 14 day Average True Range), to move between $0.0235 and $0.0325, which gives a possible trading interval of +/-$0.0089 (+/-37.93%) up or down from last closing price. If Adaptimmune Therapeutics Plc takes out the full calculated possible swing range there will be an estimated 37.93% move between the lowest and the highest trading price during the day.
Since the stock is closer to the support from accumulated volume at $0.0276 (1.43%) than the resistance at $0.0300 (7.14%), our systems sees the trading risk/reward intra-day as attractive and believe profit can be made before the stock reaches first resistance..
Is Adaptimmune Therapeutics Plc stock A Buy?
The Adaptimmune Therapeutics Plc stock holds several negative signals and despite the positive trend, we believe Adaptimmune Therapeutics Plc will perform weakly in the next couple of days or weeks. Therefore, we hold a negative evaluation of this stock.
Current score:
-2.346
Sell Candidate
Unchanged
Predicted Fair Opening Price
Predicted fair opening price on August 11, 2026 - $0.0278 ( 0.595%).
Want to trade but not sure how?
Our step-by-step guide can help.
Skip the guide? Open account with our trusted broker* 
*Your capital is at risk
ADAPY Performance
Trading levels for ADAPY
Fibonacci Support & Resistance Levels
| Level | Price | |
|---|---|---|
| R3 | 0.0323 | 15.48% |
| R2 | 0.0306 | 9.34% |
| R1 | 0.0296 | 5.54% |
| Price | 0.0280 | |
| S1 | 0.0261 | -6.73% |
| S2 | 0.0251 | -10.53% |
| S3 | 0.0233 | -16.67% |
Accumulated Volume Support & Resistance Levels
| Level | Price | |
|---|---|---|
| R3 | 0.0315 | 12.50% |
| R2 | 0.0304 | 8.57% |
| R1 | 0.0300 | 7.14% |
| Price | 0.0280 | |
| S1 | 0.0276 | -1.43% |
| S2 | 0.0270 | -3.57% |
| S3 | 0.0268 | -4.29% |
FAQ
Click here for our free guide on how to buy Adaptimmune Therapeutics Plc Stock.
Buy ADAPY